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DNA fragmentationAbstract Ellagitannins are esters of glucose with hexahydroxydiphenic acid; when hydrolyzed, they
yield ellagic acid (EA), the dilactone of hexahydroxydiphenic acid. EA has been receiving the most
attention, because it has potent antioxidant activity, radical scavenging capacity, chemopreventive
and antiapoptotic properties. Hepatocellular carcinoma (HCC) is the most frequent primary malig-
nancy of liver, and accounts for as many as one million deaths worldwide in a year. The aim of the
present study was to evaluate the antioxidant and chemopreventive efﬁciency of ellagic acid against
N-nitrosodiethylamine (NDEA) induced hepatocarcinogenesis in rats. Rats were classiﬁed into four
groups as follows: normal control group, group injected i.p. with a single dose (200 mg/kg b.wt.) of
NDEA, third group daily administered orally EAwith a dose of 50 mg/kg b.wt. for 7 days before and
14 days after NDEA administration, and fourth group received a similar dose of EA for 21 days after
the dose of NDEA administration. The model of NDEA-injected hepatocellular carcinomic (HCC)
rats elicited signiﬁcant declines in liver antioxidant enzyme activities; glutathione peroxidase (GPX),
gamma glutamyl transferase (c-GT) and glutathione-S-transferase (GST), with a reduction in
reduced glutathione (GSH) and serum total protein with concomitant signiﬁcant elevations in tumor
markers arginase and a-L-fucosidase, and liver enzymes; aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP), and glutathione-S-transferase (GST), glucose-
6-phosphate dehydrogenase (G6PD), direct and total bilirubin. The oral administration of EA as a
protective agent, produced signiﬁcant increases in tested antioxidant enzyme activities and serum
total protein concomitant with signiﬁcant decreases in the levels of tumor markers arginase and
590 R.H. Hussein, F.K. Khalifaa-L-fucosidase as well as liver enzymes, direct and total bilirubin. Similarly, the oral administration of
EA, as a curative agent produced similar changes to those when EA was used as a protective agent,
but to a lesser extent. In addition, it was noted that HCC rats exhibited a degree of DNA fragmen-
tation; however, EA administration partially inhibited the DNA fragmentation. Therefore, EA has
the ability to scavenge free radicals, prevent DNA fragmentation, reduce liver injury and protect
against oxidative stress.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Hepatocellular carcinoma (HCC) is the most frequent primary
malignancy of the liver and accounts for as many as one mil-
lion deaths worldwide in a year. In some parts of the world,
it is the most common form of internal malignancy and the most
common cause of death from cancer (Caillot et al., 2009).
Well-known risk factors of hepatocellular carcinoma include
hepatitis B virus (HBV), hepatitis C virus (HCV), aﬂatoxins,
alcohol and oral contraceptives (Gurtsevitch, 2008). One
approach to control liver cancer is chemoprevention, when
the disease is prevented, slowed or reversed substantially
by the administration of one or more non-toxic naturally
occurring or synthetic agents. In this regard, recently naturally
occurring polyphenols are receiving increased attention
because of their promising efﬁcacy in several cancer models
(Caillot et al., 2009).
Classically, markers are synthesized by the tumor and re-
leased into the circulation, but it may be produced by normal
tissues in response to invasion by cancer cells (Beﬂer and
Bisceglie, 2002). A variety of substances, including enzymes,
hormones, antigens, and proteins may be considered as tumor
markers. Analysis of tumor markers can be used as an indica-
tor of tumor response to therapy. Sensitive and speciﬁc liver
cancer marker enzymes are used as indicators of liver injury.
Analysis of these marker enzymes reﬂects mechanisms of cellu-
lar damage and subsequent release of proteins and extracellu-
lar turnover (Thirunavukkarasu and Sakthisekaran, 2003).
Ellagitannins are esters of glucose with hexahydroxydiphe-
nic acid; when hydrolyzed, they yield EA, the dilactone of
hexahydroxydiphenic acid. EA has been receiving the most
attention, because it has potent antioxidant activity, radical
scavenging capacity, chemopreventive (Turk et al., 2008) and
antiapoptotic properties.
Ellagic acid (EA) (3,7,8-tetrahydroxy[1]-benzopyrano[5,4,3-
benzopyran-5,10-dione) is a member of ﬂavanoids. It is found
in plants in the form of hydrolyzable tannins called ellagitan-
nins. The most rich dietary sources include walnuts, pome-
granates, strawberries, blackberries, cloudberries and
raspberries (Bin et al., 2013).
It contains four hydroxyl groups and two lactone groups in
which the hydroxyl group is known to increase antioxidant
activity in lipid peroxidation and protect cells from oxidative
damage (Pari and Sivasankari, 2008). Berries are the most
EA rich fruits and they are highly consumed by humans world-
wide. The presence of EA in seeds has been demonstrated by
Bushman et al. (2004), who reported that red and black rasp-
berry seeds contain 8.7 and 6.7 mg/g seed of EA, respectively.
EA is a very stable compound and is readily absorbed through
the gastrointestinal system in mammals, including humans
(Falsaperla et al., 2005).N-nitrosodiethylamine (NDEA) is a potent hepatocarcino-
genic dialkyl nitrosamine present in tobacco smoke, cured and
fried meats and in a number of beverages. It is the most char-
acterized system of xenobiotic-induced hepatocarcinogenicity
and is a common screening model to evaluate the hepato-
protective potential of drugs with antioxidant properties
(Dakshayani et al., 2005).
Thus, the aim of the present study was to evaluate the
chemopreventive efﬁciency of EA against NDEA-induced
hepatocarcinogenesis in rats. The protective effect of EA on
NDEA-induced liver carcinoma was assessed by evaluating
the enzymatic and nonenzymatic antioxidants and DNA
fragmentation, along with liver function tests.
2. Materials and methods
2.1. Chemicals
EA and NDEA were obtained from Sigma–Aldrich Chemical
Co., St. Louis, MO, USA. Carbon tetrachloride (CCl4) was
obtained from El-Gomhorya Company, Cairo, Egypt.
Biochemical kits for serum analysis were purchased from
Bio-Diagnostic Company for Chemicals, Dokki, Egypt.
2.2. Rats and diet
Thirty-six male adult Albino rats were supplied from the
breeding unit of the Egyptian Organization for Biological
Products and Vaccines (Helwan, Egypt), weighing 120–130 g.
Rats were randomly divided into 4 groups of 8 animals
each. The groups were classiﬁed as follows:
Group 1: Normal control untreated rats.
Group 2: Rats were injected with NDEA and CCl4 in order
to induce hepatocellular carcinoma.
Group 3: Rats were orally administered EA at 50 mg/kg/
day for 7 days before, and 14 days after NDEA injection
as a protective agent against liver injury induced by NDEA.
[HCC-EA(P) group].
Group 4: Rats were orally administered EA at 50 mg/kg/
day for 21 days after NDEA injection as a curative agent
against liver injury induced by NDEA. [HCC-EA(C)
group].
2.3. Induction of hepatocellular carcinoma
Rats were given a single intraperitoneal dose of NDEA
(200 mg/kg b.wt.), followed by subcutaneous injection of car-
bon tetrachloride (CCl4) (200 mg/kg b.wt.) once weekly for
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scribed by Sundaresan and Subramanian (2003).
2.4. Ellagic acid treatment
EA administered dose in this study was 50 mg/kgb.wt./day in
dimethyl sulfoxide (DMSO); orally according to Buniatian
(2003).
Clinical signs and general appearance were checked daily,
at the end of the experimental period; animals were fasted
overnight but allowed free access to water. Animals were sac-
riﬁced under anesthesia with diethyl ether, and then blood was
collected. The serum was separated by allowing blood samples
left for 15 min at temperature of 25 C then centrifuged at
4000 rpm for 20 min, then kept in plastic vials at 20 C until
analysis. The abdomen was excised; then liver was removed
immediately by dissection, washed in ice-cold isotonic saline
and blotted between two ﬁlter papers. The livers were wrapped
in aluminum foil and stored at 80 C and kept for further
determinations.
2.5. Determination of liver enzymatic and non-enzymatic
antioxidant status
One portion of liver was used to prepare 10% homogenate in
1.15% KCl and 5% homogenate in 3% sulfosalicylic acid, cen-
trifuged at 4000 rpm at 4 C for 20 min and the supernatants
were used to obtain the cytosolic fraction which was used for
the assay of GPX (Arthur and Boyne, 1985), c-GT (Szasz,
1969), GST (Habig et al., 1974) and GSH (Ellman, 1959).
2.6. Serum biochemical determinations
In serum the following parameters were estimated: arginase en-
zyme activity according to Patil et al. (1990), a-L-fucosidase
activity according to Wang and Cao (2004) as tumor markers’
activities, alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) according to Kaplan (1984), alkaline
phosphatase (ALP) according to Belﬁeld and GoldbergTable 1 Effect of oral administration of ellagic acid on serum tumo
carcinomic rats.
Parameters Groups
Control
Arginase enzyme activity (U/L) 322.5 ± 5.8
a-L-Fucosidase activity (nmol/ml/h) 62.6 ± 2.5
Table 2 Effect of oral administration of ellagic acid on hepatic
hepatocellular carcinomic rats.
Parameters Groups
Control
(GSH) (lmol/dl) 40.21 ± 0.12
(GPX) (nmol/ml) 93.2 ± 9.4
(c-GT) (nmol/mg protein) 98.1 ± 7.1
(GST) (nmol/mg protein/min) 234.3 ± 12.4(1971), glucose-6-phosphate dehydrogenase (G6PD) according
to Sies et al., (1967) serum total protein, total and direct
bilirubin according to Lowry et al. (1951) and Martinek (1966).
2.7. DNA fragmentation analysis
Another portion of liver tissues was homogenized and incu-
bated in 100 mM Tris–HCl (pH 8.0), 25 mM EDTA, 0.5%
SDS, and 0.1 lg/ml proteinase K at 60 C for 3 h. DNA was
extracted with phenol/chloroform (1:1 v:v) and chloroform/
isoamyl alcohol (1:24 v:v). The extracted DNA was precipi-
tated and digested in 10 mM Tris–HCl (pH 5.0) containing
1 mM EDTA and 10 lg RNase for 1 h at 37 C. Five micro-
grams of DNA per sample was electrophoretically separated
on 1.5% agarose gel containing 0.5 lg/ml ethidium bromide.
The DNA pattern was examined by an ultraviolet transillumi-
nator (Sambrook et al., 1989).
2.8. Statistical analysis
The obtained results were expressed as mean ± SE. Data were
evaluated statistically with computerized SPSS package pro-
gram (SPSS 9.00 software for Windows) using one-way analy-
sis of variance (ANOVA). Signiﬁcant differences among means
were estimated at p< 0.05 according to Snedecor and Coch-
ran (1986).
3. Results
Table 1 shows that administration of NDEA elicited dramatic
signiﬁcant increase (p< 0.05) in the tumor markers arginase
and a-L-fucosidase activities (+26% and +234.5%, respec-
tively) in the untreated HCC group, compared to normal con-
trol rats. HCC-EA(P) pretreated rats showed signiﬁcant
reduction in arginase and a-L-fucosidase activities (23.6%
and 61.9%, respectively) as compared to HCC rats. How-
ever, rats in the HCC-EA(C) group elicited lower decreases
(7.5% and 22.6%) in arginase and a-L-fucosidase activities
respectively as compared to HCC rats.r markers: arginase and a-L-fucosidase activities in hepatocellular
HCC rats HCC-EA(C) HCC-EA(P)
406.0 ± 7.8 375.3 ± 10.9 310.0 ± 9.4
209.4 ± 4.3 112.0 ± 4.2 79.7 ± 5.3
concentrations of GSH, GPX, c-GT and GST activities of
HCC rats HCC-EA(C) HCC-EA(P)
25.42 ± 0.25 30.85 ± 0.6 38.9 ± 0.25
49.9 ± 3.4 73.8 ± 2.6 91.8 ± 0.6
152.8 ± 10.6 122.6 ± 8.3 110.3 ± 4.3
361.8 ± 9.68 284.5 ± 17.3 254.7 ± 19.2
Lane4       lane3      lane2       lane1     
Figure 1 Inﬂuence of ellagic acid on NDEA-induced hepatic
DNA fragmentation. Lane 1: no DNA fragmentation in normal
control. Lane 2 depicts strong DNA fragmentation in NDEA-
treated HCC rats. Lane 3 depicts weak DNA fragmentation in
HCC-EA(C) rats. Lane 4 depicts no DNA fragmentation in rats
administered with EA before and after NDEA injection, HCC-
EA(P) rats.
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signiﬁcant decreases in the activities of the liver antioxidant en-
zymes: GSH and GPX by 36% and 46.4% respectively,
compared to normal controls. Oral administration of EA elic-
ited dramatic increase in these enzymes, this increase was more
pronounced in HCC-EA(P)-pretreated rats +53% and
+83.9% than in HCC-EA(C) treated ones +21% and
+47.8% for GSH and GPX respectively as compared to
NDEA intoxicated rats. On the other hand, the increased
activities of c-GT and GST that were induced by NDEA in
HCC rats (+55.7% and +54.4%, respectively) when com-
pared to normal control rats. EA supplementation to HCC
rats decreased the levels of c-GT and GST activities compared
to HCC rat group. These changes were more pronounced in
HCC-EA(P)-pretreated rats than in HCC-EA(C)-treated ones.
The levels of reduction of c-GT and GST activities were
27.8% and 29.6% respectively, in HCC-EA(P)-pretreated
rats, while they were 19.7% and 27.8% in HCC-EA(C)-
treated rats when compared to HCC rats (Table 2).
Table 3 shows that NDEA intoxication resulted in liver car-
cinoma which was manifested by signiﬁcant increase in serum
ALT, AST, ALP and G6PD activities by +87.7%, +98.1%,
+47.5% and +70.19%, respectively when compared to nor-
mal control rats, thus indicating liver damage. Oral adminis-
tration of EA to HCC rats signiﬁcantly reduced the elevated
levels of ALT, AST, and ALP activities along with more
increasing activity of G6PD. HCC-EA(P) pretreated rats
showed signiﬁcant changes in the enzyme activities by
43.9%, 45.8%, 28.5% and +106.4%, respectively when
compared to HCC rats. However, rats in the HCC-EA(C) rats
elicited lower decreases in these enzyme activities 35.3%,
14.2%, 23.25 and +87.14%, respectively when compared
to HCC rats.
Table 4 shows that NDEA-intoxication resulted in a signif-
icant reduction in serum total protein level by 28.4% com-
pared to normal controls (p< 0.05) this change was
increased by +28.6% and +6.5% in HCC-EA(P) and HCC-
EA(C) groups respectively, as compared to NDEA treated
rats. On the other hand, the levels of direct and total bilirubin
signiﬁcantly reduced in HCC rats by 59.3% and 80%,Table 3 Effect of oral administration of ellagic acid on serum activ
rats.
Parameters Groups
Control H
(AST) (U/L) 106.00 ± 8.91 1
(ALT) (U/L) 76.70 ± 3.37 1
(ALP) (U/L) 190.97 ± 4.48 2
G6PD (mol/mg protein/min) 27.85 ± 2.29
Table 4 Effect of oral administration of ellagic acid on serum
hepatocellular carcinomic rats.
Parameters Groups
Control HC
Total protein (g/dl) 6.82 ± 0.10 4.8
Direct bilirubin (mg/dl) 0.59 ± 0.01 0.9
Total bilirubin (mg/dl) 0.45 ± 0.01 0.8respectively indicating liver injury. EA administration elicited
dramatic increase in direct and total bilirubin levels by
+15.9% and +35.8% in HCC-EA(P) pretreated rats and by
+3.3% and +20.9% in HCC-EA(C) treated rats respectively,
when compared to HCC rats.
3.1. Liver DNA
NDEA-treated HCC rats showed a degree of hepatic DNA
fragmentation which was nearly abolished in ellagic acid trea-
ted rats (Fig. 1).
4. Discussion
An understanding of how cancer may be prevented is one of
the key objectives of the recent researches. This can be
achieved to some extent by using chemopreventive agents,ities of AST, ALT, ALP and G6PD of hepatocellular carcinomic
CC rats HCC-EA(C) HCC-EA(P)
99.00 ± 9.72 128.6 ± 9.98 111.5 ± 7.9
52.00 ± 3.33 130.3 ± 2.98 82.3 ± 3.5
81.09 ± 4.80 215.8 ± 3.78 200.7 ± 3.9
47.4 ± 1.48 52.12 ± 4.04 57.50 ± 4.84
concentrations of total protein, direct and total bilirubin of
C rats HCC-EA(C) HCC-EA(P)
8 ± 0.43 5.2 ± 0.46 6.69 ± 0.45
4 ± 0.02 0.61 ± 0.03 0.79 ± 0.06
1 ± 0.01 0.67 ± 0.03 0.52 ± 0.05
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the process of tumor development. Therefore, it is essential
to identify agents as well as to evaluate their efﬁcacy and to
elucidate their mechanisms of action.
In the present study, serum obtained from tumor bearing
rats showed signiﬁcant increase in tumor markers arginase
and fucosidase, AST, ALT, ALP, GST, G6PD, direct and to-
tal bilirubin along with signiﬁcant decrease in serum total pro-
tein, GSH, GPX and c-GT compared to control animals. The
elevation of these enzyme activities was indicative of the toxic
effect of NDEA on the liver tissue. It is known that N-nitroso
compounds act as strong carcinogens in various mammals
including primates (Swenberg et al., 1991). NDEA has been
shown to be metabolized by cytochrome P-450 (CYP 2E1) to
its active ethyl radical metabolite, which could interact with
DNA causing mutation and carcinogenesis (Anis et al., 2001).
Liver injuries induced by NDEA followed by CCl4 injection
are the best-characterized system of the xenobiotic-induced
hepatotoxicity and is a commonly used model for screening
the antihepatotoxic/hepatoprotective activity of drugs (Lin
et al., 2008). At a suitable dose, CCl4 causes extensive necrosis
in the liver centrilobular regions around the central veins. CCl4
is biotransformed by the cytochrome P450 in the liver endo-
plasmic reticulum to the highly reactive trichloromethyl free
radical (CCl3). This free radical in turn reacts with oxygen to
form a trichloromethylperoxy radical, which leads to elicit
lipid peroxidation, elevation of hepatic enzymes and ﬁnally
results in cell death (Bun et al., 2006).
NDEA elicited dramatic signiﬁcant increase in the tumor
markers arginase and a-L-fucosidase activities compared to
normal control rats.
Tumor markers are potential screening tools that are widely
used for early diagnosis of tumors. Arginase (L-arginine ureo-
hydrolase) is present in mammals and plants. In humans, argi-
nase is expressed predominantly in the liver, and to lesser
degrees in the breast, kidney, testes, salivary glands, epidermis
and erythrocytes. Arginase catalyzes the conversion of arginine
to ornithine and urea, completing the last step in the urea cycle.
Arginase activity is a key diagnostic indicator so it has been
reported that, some of the urea cycle enzymes leak rapidly from
hepatocytes when liver cells are damaged (Merrick et al., 2006).
Many studies have shown that increased stimulation of
arginase expression in animal systems leads to production of
polyamines that promote tumor cell proliferation and wound
healing (Satriano, 2003) and (Cederbaum et al., 2004).
a-L-Fucosidase enzyme is usually found as a soluble compo-
nent of the lysosome and functions as an acid hydrolase in
the degradation of a diverse group of naturally occurring
fugoglycoconjugate. Increased level of this enzyme is an early
indication of HCC. However, it has been proposed as a
sensitive tumor marker (Othman et al., 2011).
A study by Sivaramakrishnan et al. (2007) found that the
serum a-L-fucosidase activity level in patients with HCC is
higher than patients with liver cirrhosis these ﬁndings suggest
that an increase in serum a-L-fucosidase activity in patients
with cirrhosis is the primary risk factor for developing HCC.
Oral supplementation with EA reduced the serum enzyme lev-
els when compared to the HCC rat group. The dose of EA
(50 mg/kg b.w.) used in the study is safe because some toxico-
logical evaluation revealed that blood coagulation may occur
following intravenous injection of large doses (100 mg/kg b.wt.)
(Sungwoo et al., 2010).The antitumor activity of EA has proven an effective inhib-
itor of chemically induced cancer in the hepatic systems of
mice (Han et al., 2006). Several mechanisms by which phyto-
chemicals, such as ellagic acid, can alter carcinogenesis have
been identiﬁed. Potential mechanisms include the inhibition
of enzymes; modiﬁcation of carcinogen detoxiﬁcation through
several pathways; antioxidation activities, including scaveng-
ing DNA reactive agents; suppressing abnormal proliferation
of early preneoplastic lesions; and inhibiting certain properties
of the cancer cell (Ceribas et al., 2010). Ellagic acid has been
shown to have the potential to be a useful cancer preventive
and/or chemotherapeutic agent. It decreases the rate of carcin-
ogen metabolism by directly inhibiting the catalytic activity
and frequency of gene expression (Yu et al., 2005). Another
mechanism was included to reduce carcinogens by the effect
of EA on quinone reductase (QR), it is a detoxiﬁcation en-
zyme, functions to prevent the formation of superoxide radi-
cals and detoxify a variety of foreign compounds. Carlsen
et al. (2003) found that dietary ellagic acid signiﬁcantly in-
creased hepatic QR activity by 9- and 2-fold, respectively. In
this way, ellagic acid effectively increases detoxiﬁcation of car-
cinogens and reduces mutagenesis and tumorigenesis. Further
studies of the structure–function relationship indicated an
interaction between the lactones of EA and antioxidant
responsive elements (Wedge et al., 2001). A study by Juranic
et al. (2005) demonstrated that, EA possess the potential for
antiproliferative action against human colon carcinoma cells
in vitro.
Hepatocellular carcinoma was assessed by biochemical
ﬁndings, serum GSH, GPX, GST and c-GT. A study by
Dakshayani et al. (2005) demonstrated that the oxidative stress
may be the reason for the elevated lipid peroxidation level in the
liver of NDEA injected rats. Reactive oxygen species (ROS)
are produced during the metabolism of NDEA or during the
process of carcinogenesis (Sundaresan and Subramanian,
2003). The higher mean activities of the antioxidant enzymes
GSH and GPX seen in the ellagic acid treated group highlight
the putative anti-radical and antioxidant effects of ellagic acid
(Priyadarsini et al., 2002).
GSH is a tripeptide (L-c-glutamylcysteinylglycine), it is crit-
ical for cellular protections such as detoxiﬁcation of ROS con-
jugation and excretion of toxic molecules and control of
inﬂammatory cytokine cascade .Depletion of GSH in tissues
leads to impairment of the cellular defense against ROS, and
may result in peroxidative injury, thus GSH is involved in
many cellular processes including the detoxiﬁcation of endog-
enous and exogenous compounds (Zaidi et al., 2005). Our ﬁnd-
ings are consistent with Pradeep et al. (2007) which showed
that GSH concentration is decreased after NDEA injection.
The capacity of a tumor cell to maintain GST is determined
by a number of interacting pathways. Many of the enzymes in-
volved in these pathways have been targeted for therapeutic
intervention by modulators of anticancer drug resistance. In-
crease in the expression of GST in multi-drug resistance cell
lines has frequently been cited as a causal resistance mecha-
nism, since glutathione is required to maintain the normal re-
duced state of cells and to counteract all the deleterious effects
of oxidative stress (Tew, 1994). Ellagic acid has been shown to
regulate intracellular GSH levels by induction of gamma-glut-
amylcysteine synthetase (Bansal et al., 2005), and to prevent n-
nitrosodiethylamine induced tumorigenesis by enhancing the
GSH-dependent protection. Similarly, Hassoun et al. (2004)
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and c-GT in liver of ellagic acid-treated mice.
The scavenging action of EA on both oxygen and hydroxyl
radicals, and inhibition of lipid peroxidation formation in vitro
and in vivo, have also been documented by Iino et al. (2001).
Turk et al. (2010) claimed that ellagic acid may act as a good
lipophilic antioxidant, due to its solubility; it exhibits mini-
mum solubility in water, however, its solubility increases in
organic solvents such as methanol and dimethyl sulfoxide
(DMSO). It has been shown that two lactone groups of
EA can act as a hydrogen bond donor and acceptor, which
might be involved in the free radical scavenging action of
EA (Gil et al., 2000).
In HCC rats, it was observed that, the enzyme levels were
signiﬁcantly increased by NDEA injection. These results agreed
with those obtained byMittal et al. (2006) who found that activ-
ities of AST, ALT and ALP were increased signiﬁcantly follow-
ing nitroso compound treatment in rats due to substantial liver
damage. Moreover, Vozarova et al. (2002) mentioned that the
elevated activities of AST, ALT and ALP enzymes were signs
of impaired liver functions in response to NDEA administra-
tion, the elevation of liver enzymes occurred due to their release
from the cytoplasm into the blood circulation after rupture of
the plasma membrane and cellular damage.
Treatment with EA reduced the activities of the elevated en-
zymes, a study by Leelavinothan and Ramasamy (2008) exam-
ined the ability of different concentrations of EA (30, 50, 60
and 90 mg/kg body weight) to decrease the activities of ALT
and ALP in the plasma of liver injured rats. The study con-
cluded that, administrations of EA at 50 mg/kg b.wt., signiﬁ-
cantly decreased the activities of hepatic marker enzymes
compared with other doses of EA. This can be attributed to
the antioxidant properties of EA. This result agreed with a
study by Devipriya et al. (2007) which demonstrated the role
of ellagic acid in reducing elevated enzyme levels and exerting
preventive effects against chronic alcohol-induced liver dam-
age in rats.
Glucose-6-phospahe dehydrogenase G6PD is an enzyme
that catalyzes the ﬁrst step in the hexose monophosphate path-
way, produces ribose, which is incorporated into nucleotides
and NADPH, the major cytoplasmic reducing compound.
NADPH is a substrate for phase I and II detoxiﬁcation en-
zymes. G6PD is elevated in response to external stimuli like
toxic agents and oxidative stress. Frederiks et al. (2003) found
that the activity of G6PD is up regulated by carcinogens and
oxidative stress. EA administration to NDEA-treated rats
showed elevated G6PD activity, indicating that increased
amounts of NADPH are required for detoxiﬁcation process.
Serum total protein is present in blood plasma abundantly
(60%) and structurally well characterized. In the present study
it was observed that, the administration of NDEA decreased
the levels of serum total protein which is an evidence of exis-
tence of liver toxicity when compared to normal animals. Stud-
ies have shown that cellular proteins may be affected by free
radical accumulation leading to the formation of carbonyl
derivatives. The carbonyl derivatives of proteins may result
from oxidative modiﬁcation of amino acid side chains and
reactive oxygen-mediated peptide cleavage (Afaq et al., 2004).
Further, Bala et al. (2006) have reported that the primary
target of the oxygen-radical attack, promoted by ethanol, is
represented on cellular proteins.Treatment with EA signiﬁ-
cantly increased the levels of total protein because itwould prevent the attack of free radicals on amino acids and
thus diminish the production of the carbonyl group in
EA-treated rats.
In this study, direct and total bilirubin concentrations were
elevated in NDEA treated rats, this elevation may be due to
decreased conjugation and decreased secretion from the liver
or blockage of bile ducts (Bun et al., 2006). EA reduced the ele-
vated levels of total and direct bilirubin in HCC rats. In a
study by Talcott and Lee (2002), protective effects of 14 kinds
of antioxidants on liver injury induced by carbon tetrachloride
(CCl4) were investigated in terms of bilirubin concentration,
consequently, the signiﬁcant protective effects were found in
ellagic acid, the biochemical restoration of bilirubin is due to
the promoting effect of EA on bile glucoronidation.
NDEA followed by CCl4 injection was found to induce
apoptosis as represented by DNA fragmentation. This result
came in agreement with Castro et al. (1993) who reported that
CCl4 induced necrosis and DNA fragmentation in Sprague–
Dawley male rats. Nabeshima et al. (2006) proved that carbon
tetrachloride poisoning induced DNA fragmentation, apopto-
sis and necrosis in rat liver by immuno-histochemical labeling
of nuclear DNA fragmentation, ﬂow cytometry and gel elec-
trophoresis. Several reactive mutagenic and genotoxic lipid
peroxidation products have been identiﬁed to bind to DNA
and to damage it (Eder et al., 2006). Damage to DNA may
lead to mutations, initiation of cancer cells and cancer progres-
sion (Walle et al., 2003).
Ellagic acid is an effective antimutagen and anticarcinogen
phytotherapeutic agent, that prevents carcinogens binding to
DNA and strengthens connective tissue and thus may keep
cancer cells from spreading, inhibits cancer onset and tumor
proliferation and protects healthy cells during chemotherapy
(Turk et al., 2008).
One method by which cancer affects DNA is through cova-
lent bonding of the carcinogen to the DNA molecule. Ellagic
acid inhibits mutagenesis and carcinogenesis by forming ad-
ducts with DNA, thus masking binding sites to be occupied
by the mutagen or carcinogen (Eder et al., 2006). Another
mechanism by Nair et al. (2005) showed that, EA inhibits sev-
eral different types of DNA modifying enzymes including
topoisomerases I and II, gyrase and polymerase and hence
inhibits the growth of cancerous cells.
When EA bind to DNA its molecules could be positioned in
such a way, so it could effectively scavenge reactive intermedi-
ates that approach the critical sites on DNA. EA may also di-
rectly interact with the ultimate reactive metabolites of
carcinogen by donating their electrons and rendering it inac-
tive. There was a great relation between lipid peroxidation
and DNA damage, existing evidence suggests that lipid perox-
idation products of polyunsaturated fatty acids play a major
role in genotoxicity of the cell (Kim et al., 2009). A study by
Walle et al. (2003) aimed to evaluate the effect of polyphenols
on DNA showed that; the binding of EA to DNA was as much
as 500 times higher than for quercetin. This large difference
may be due to the greater ability of EA than quercetin to inter-
calate with the double-stranded DNA molecule.5. Conclusion
The data obtained from this study, indicate that oral adminis-
tration of ellagic acid (which has potent free radical scavenging
The protective role of ellagitannins ﬂavonoids pretreatment against N-nitrosodiethylamine 595and antioxidant properties) to HCC rats, at least partially,
alleviates NDEA-induced liver injury by preventing lipid per-
oxidation enzyme system, inhibiting DNA fragmentation,
and increasing antioxidant enzyme activities. Moreover, the
use of EA prior to NDEA treatment (as protection) is more
effective than its curative effect (i.e., when ellagic acid admin-
istered after NDEA treatment) in preventing NDEA-induced
liver injury. Therefore, EA administration seems to be a highly
promising agent for protecting hepatic tissue against oxidative
damage and in preventing hepatic injury and dysfunction.References
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